Relmada Therapeutics, Inc. Product Segmentation & Forecast - 2015

1
Relmada Therapeutics, Inc. Product Pipeline
Review - 2015
Published on October - 2015
2
.
Report Overview
About Relmada Therapeutics, Inc. Product Pipeline
Review 2015 Global Markets Directs, Relmada
Therapeutics, Inc. Product Pipeline Review -
2015, provides an overview of the Relmada
Therapeutics, Inc.s pharmaceutical research and
development focus. This report provides
comprehensive information on the current
therapeutic developmental pipeline of Relmada
Therapeutics, Inc. s, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type. It also reviews latest updates, and
featured news and press releases, along with
special features on late-stage and discontinued
projects. Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary data bases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/relm
ada-therapeutics-inc-product-pipeline-review-2015-
market
3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of Relmada Therapeutics, Inc.
including business description, key information
and facts, and its locations and subsidiaries The
report reviews current pipeline of Relmada
Therapeutics, Inc. s human therapeutic division
and enlists all their major and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Relmada Therapeutics, Inc. s pipeline
products   Reasons to buy Evaluate Relmada
Therapeutics, Inc. s strategic position with
total access to detailed information on its
product pipeline Assess the growth potential of
Relmada Therapeutics, Inc. in its therapy areas
of focus Identify new drug targets and
therapeutic classes in the Relmada Therapeutics,
Inc. s RD portfolio and develop key strategic
initiatives to reinforce pipeline in those
areas Exploit in-licensing opportunities by
identifying windows of opportunity to fill
portfolio gaps
5
Report Overview

• Develop strategic initiatives by understanding
  the focus areas of Relmada Therapeutics, Inc. and
  exploit collaboration and partnership
  opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of
  Relmada Therapeutics, Inc.
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Relmada Therapeutics, Inc. and identify potential
  opportunities in those areas
• Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 4List of Figures 4Relmada
Therapeutics, Inc. Snapshot 5Relmada
Therapeutics, Inc. Overview 5Key Information
5Key Facts 5Relmada Therapeutics, Inc. -
Research and Development Overview 6Key
Therapeutic Areas 6Relmada Therapeutics, Inc. -
Pipeline Review 8Pipeline Products by Stage of
Development 8Pipeline Products - Monotherapy
9Relmada Therapeutics, Inc. - Pipeline Products
Glance 10Relmada Therapeutics, Inc. - Late Stage
Pipeline Products 10Phase III Products/Combinatio
n Treatment Modalities 10
7
Table Of Contents
Relmada Therapeutics, Inc. - Clinical Stage
Pipeline Products 11Phase II Products/Combination
Treatment Modalities 11Phase I
Products/Combination Treatment Modalities
12 Relmada Therapeutics, Inc. - Early Stage
Pipeline Products 13Preclinical
Products/Combination Treatment Modalities
13Relmada Therapeutics, Inc. - Drug Profiles
14MGN-1703 14Product Description 14Mechanism
of Action 14RD Progress 14MGN-1601 18Product
Description 18Mechanism of Action 18RD
Progress 18
8
Table Of Contents
MGN-1404 20 Product Description 20Mechanism of
Action 20RD Progress 20MGN-1331 21Product
Description 21Mechanism of Action 21RD
Progress 21MGN-1333 22  Enquiry about this
report _at_ http//www.researchbeam.com/relmada-thera
peutics-inc-product-pipeline-review-2015-market/en
quire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/relmada-therapeutics-i
nc-product-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com